This proposal aims to test an innovative new paradigm for the regulation of the sodium pump in the CNS. The sodium pump (Na,K-ATPase) consumes half of all the energy used in the brain. It is stably inhibited in ischemic tissue, which potentiates excitotoxicity. It contributes to neural and glial physiology through its regulation of Na and K and its electrogenic contribution to membrane potential. There is much evidence that it is actively regulated by transmitters and hormones, but the mechanisms remain frustratingly elusive at the molecular and biochemical level. We have recently shown that the Na,K-ATPase """"""""gamma subunit"""""""" of the kidney acts as an accessory protein, modulating the Na,K-ATPase by reducing its affinity for Na and K. Others have shown that a homologue, CHIF, has a functionally opposite effect on kidney sodium pump properties, and the two are expressed in different nephron segments. These proteins are not expressed in the brain, but we have identified five other homologs that are. We will test the new hypothesis that they are all Na,K-ATPase regulators. The homologs (the FXYD gene family) share a conserved central membrane domain, but have divergent extracellular and intracellular domains. This predicts that they have different functional effects and are targeted by different regulatory mechanisms. In our preliminary data we show that one of the homologs is restricted to the cerebellar cortex molecular layer, and that it indeed associates with Na, K-ATPase. We will determine whether the other homologs have different cellular distributions, interact with different Na,K-ATPase isoforms, and have different functional effects on Na, K-ATPase properties. Two of them are new gene products that were first identified in our genomic studies, and pilot data are needed to make the transition from sequence to biology. The work promises to provide a significant breakthrough in the regulation of transport and energy metabolism in the brain, and may lead to neuroprotective therapy that could restore sodium pump activity in tissue-at-risk after stroke.

National Institute of Health (NIH)
National Institute of Neurological Disorders and Stroke (NINDS)
Exploratory/Developmental Grants (R21)
Project #
Application #
Study Section
National Institute of Neurological Disorders and Stroke Initial Review Group (NSD)
Program Officer
Stewart, Randall
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Massachusetts General Hospital
United States
Zip Code
Arystarkhova, Elena (2016) Beneficial Renal and Pancreatic Phenotypes in a Mouse Deficient in FXYD2 Regulatory Subunit of Na,K-ATPase. Front Physiol 7:88
Arystarkhova, Elena; Liu, Yi B; Salazar, Cynthia et al. (2013) Hyperplasia of pancreatic beta cells and improved glucose tolerance in mice deficient in the FXYD2 subunit of Na,K-ATPase. J Biol Chem 288:7077-85
Sweadner, Kathleen J; Pascoa, Jennifer L; Salazar, Cynthia A et al. (2011) Post-transcriptional control of Na,K-ATPase activity and cell growth by a splice variant of FXYD2 protein with modified mRNA. J Biol Chem 286:18290-300
Arystarkhova, Elena; Donnet, Claudia; Munoz-Matta, Ana et al. (2007) Multiplicity of expression of FXYD proteins in mammalian cells: dynamic exchange of phospholemman and gamma-subunit in response to stress. Am J Physiol Cell Physiol 292:C1179-91